DESTINY Calls For Daiichi Sankyo/AZ’s Enhertu In Other Indications
Gastric, Lung And Colorectal Data Promising
Executive Summary
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.
You may also be interested in...
AZ Q2 Preview: Pipeline, COVID-19 and M&A Key Focus
AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine.
Speedy EU Review For AZ/DS's Enhertu; Cheer Too For BMS/bluebird, Celgene And Rhythm
The European Medicines Agency has agreed to fast track the review of four marketing applications in recent months.The products include AstraZeneca's advanced breast cancer treatment, Enhertu, two investigational CAR-T therapies, and a potential treatment for rare genetic disorders of obesity.
Arix Assembles New Teams To Advance Portfolio
Arix Biosciences has unveiled three significant changes to the organization, including the appointment of Christian Schetter as co-managing director, which the healthcare-focused venture capitalist hopes will keep its impressive record of biotech investments on track.
Need a specific report? 1000+ reports available
Buy Reports